EUVIMEDEUVIMED entdecken
Open Access

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines

Tal Gonen, Noam Barda, Keren Asraf, Gili Joseph, Yael Weiss-Ottolenghi, Ram Doolman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

JAMA Network Open · 08.09.2023 · 6 (9) · e2332813

DOI: 10.1001/jamanetworkopen.2023.32813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 08.09.2023. Verfasst von Tal Gonen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. Hauptthemen laut MEDLINE: COVID-19, Influenza Vaccines. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance COVID-19 and seasonal influenza vaccines were previously given separately, although their coadministration is warranted for vaccination adherence. Limited data on their coadministration have been published.

Objective

To compare the reactogenicity and immunogenicity of COVID-19 and influenza vaccinations administered together with those of COVID-19 vaccination alone. Design, Setting, and Participants This prospective cohort study included health care workers at a large tertiary medical center in Israel who received the Influvac Tetra (Abbott) influenza vaccine (2022/2023), the Omicron BA.4/BA.5–adapted bivalent (Pfizer/BioNTech) vaccine, or both. Vaccination began in September 2022, and data were collected until January 2023. Vaccines were offered to all employees and were coadministered or given separately. Adverse reaction questionnaires were sent, and serologic samples were also collected. Exposures Receiving COVID-19 vaccine, influenza vaccine, or both. Main Outcomes and Measures The main outcomes for the reactogenicity analysis were symptoms following vaccine receipt, assessed by a digital questionnaire: any local symptoms; fever; weakness or fatigue; any systemic symptoms; and their duration. The immunogenicity analysis’ outcome was postvaccination anti-spike IgG titer.

Results

This study included 2 cohorts for 2 separate analyses. The reactogenicity analysis included 588 participants (of 649 questionnaire responders): 85 in the COVID-19 vaccine–alone group (median [IQR] age, 71 [58-74] years; 56 [66%] female); 357 in the influenza vaccine–alone group (median [IQR] age, 55 [40-65] years; 282 [79%] female); and 146 in the coadministration group (median [IQR] age, 61 [50-71] years; 81 [55%] female). The immunogenicity analysis included 151 participants: 74 participants in the COVID-19 vaccine group (median [IQR] age, 67 [56-73] years; 45 [61%] female) and 77 participants in the coadministration group (median [IQR] age, 60 [49-73] years; 42 [55%] female). Compared with COVID-19 vaccination alone, the risk of systemic symptoms was similar in the coadministration group (odds ratio, 0.82; 95% CI, 0.43-1.56). Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine–alone group. Conclusions and Relevance In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Influenza VaccinesFemaleHumansAgedMiddle AgedMaleCOVID-19 VaccinesCohort StudiesProspective Studies

Substanzen

Influenza VaccinesCOVID-19 Vaccines

Autor:innen und Institutionen

  • Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • ARC Innovation Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
  • Epidemiology, Biostatistics and Community Health Services, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
  • The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.

Zitieren

APA

Gonen, T., Barda, N., Asraf, K., Joseph, G., Weiss-Ottolenghi, Y., Doolman, R., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2023). Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. JAMA Network Open, 6(9), e2332813. https://doi.org/10.1001/jamanetworkopen.2023.32813

Vancouver

Gonen T, Barda N, Asraf K, Joseph G, Weiss-Ottolenghi Y, Doolman R, et al. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. JAMA Network Open. 2023;6(9):e2332813. doi:10.1001/jamanetworkopen.2023.32813

BibTeX
@article{Gonen2023,
  author = {Gonen, Tal and Barda, Noam and Asraf, Keren and Joseph, Gili and Weiss-Ottolenghi, Yael and Doolman, Ram and Kreiss, Yitshak and Lustig, Yaniv and Regev-Yochay, Gili},
  title = {Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {9},
  pages = {e2332813},
  doi = {10.1001/jamanetworkopen.2023.32813}
}
Kostenlos starten →